BioSpace News Archive

Scholar Rock (NASDAQ: SRRK) today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4 in Chicago.

Thermo Fisher Scientific Inc., the world leader in serving science, released its 2023 Corporate Social Responsibility report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

ASCO Annual Meeting – The Precision Cancer Consortium (PCC), in partnership with Massive Bio, has unveiled compelling results from a comprehensive study conducted on a multi-sponsor pharmaceutical platform.

Revvity, Inc. (NYSE: RVTY) will present at the 45 th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.

Clarametyx Biosciences Inc. today announced the appointment of Palani Palaniappan, Ph.D., to its Scientific Advisory Board, as well as the appointments of Stephen Hoffman, M.D., Ph.D. and Paul Westberg, MBA as strategic advisors.

Lucy Therapeutics, Inc. today announced it has raised $12.5 million in additional funding led by existing investors Engine Ventures and Safar Partners with new participation from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which provided a $2 million non-dilutive grant.

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).

Leveragen, Inc. announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused on the development of therapeutic antibodies.

Coya Therapeutics, Inc. announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024.

CureVac N.V. today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK.